Syndecan Family Gene and Protein Expression and Th... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer

Full text
Author(s):
Santos, Nilton Jose [1, 2] ; Barquilha, Caroline Nascimento [1, 2] ; Barbosa, Isabela Correa [1, 2] ; Macedo, Rodrigo Tavares [3] ; Lima, Flavio Oliveira [3] ; Justulin, Luis Antonio [1] ; Barbosa, Guilherme Oliveira [2] ; Carvalho, Hernandes F. [2] ; Felisbino, Sergio Luis [1]
Total Authors: 9
Affiliation:
[1] Sao Paulo State Univ, Inst Biosci Botucatu IBB, Dept Struct & Funct Biol, BR-18618689 Botucatu, SP - Brazil
[2] UNICAMP State Univ Campinas, Inst Biol IB, Dept Struct & Funct Biol, BR-13083970 Campinas, SP - Brazil
[3] Sao Paulo State Univ, Botucatu Sch Med FMB, BR-01049010 Botucatu, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 22, n. 16 AUG 2021.
Web of Science Citations: 0
Abstract

Prostate cancer (PCa) is the leading cause of cancer-associated mortality in men, and new biomarkers are still needed. The expression pattern and protein tissue localization of proteoglycans of the syndecan family (SDC 1-4) and syntenin-1 (SDCBP) were determined in normal and prostatic tumor tissue from two genetically engineered mouse models and human prostate tumors. Studies were validated using SDC 1-4 and SDCBP mRNA levels and patient survival data from The Cancer Genome Atlas and CamCAP databases. RNAseq showed increased expression of Sdc1 in Pb-Cre4/Pten(f/f) mouse Pca and upregulation of Sdc3 expression and downregulation of Sdc2 and Sdc4 when compared to the normal prostatic tissue in Pb-Cre4/Trp53(f/f)-;Rb1(f/f) mouse tumors. These changes were confirmed by immunohistochemistry. In human PCa, SDC 1-4 and SDCBP immunostaining showed variable localization. Furthermore, Kaplan-Meier analysis showed that patients expressing SDC3 had shorter prostate-specific survival than those without SDC3 expression (log-rank test, p = 0.0047). Analysis of the MSKCC-derived expression showed that SDC1 and SDC3 overexpression is predictive of decreased biochemical recurrence-free survival (p = 0.0099 and p = 0.045, respectively), and SDC4 overexpression is predictive of increased biochemical recurrence-free survival (p = 0.035). SDC4 overexpression was associated with a better prognosis, while SDC1 and SDC3 were associated with more aggressive tumors and a worse prognosis. (AU)

FAPESP's process: 16/09532-3 - Prostate cancer: changes in the Syndecan proteoglycans, oxidative stress enzyme sulfiredoxin and cell cycle kinase MELK
Grantee:Sérgio Luis Felisbino
Support Opportunities: Regular Research Grants
FAPESP's process: 19/19644-1 - Prostate cancer: involvement of adiponectin and type X collagen pathways
Grantee:Sérgio Luis Felisbino
Support Opportunities: Regular Research Grants
FAPESP's process: 15/26175-7 - Stromal alterations in prostate cancer: a study on Syndecan proteoglycans family in two knockout mouse model - PTEN-/- e Rb1-/- Trp53-/-
Grantee:Nilton José dos Santos
Support Opportunities: Scholarships in Brazil - Master